Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
32
GCTK Quote, Financials, Valuation and Earnings
Last price:
$3.96
Seasonality move
:
-7.61%
Day range:
$3.65 - $4.09
52-week range:
$3.21 - $222.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.72x
P/B ratio:
40.61x
Volume:
21.3K
Avg. volume:
56.7K
1-year change:
-97.96%
Market cap:
$111.7M
Revenue:
--
EPS (TTM):
-$1,319.98
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
GCTK
GlucoTrack, Inc.
|
-- | -- | -- | -- | -- |
|
CATX
Perspective Therapeutics, Inc.
|
$231.1K | -$0.35 | -9.65% | -37.91% | $12.3077 |
|
INFU
InfuSystem Holdings, Inc.
|
$36.7M | $0.05 | 8.36% | 39.86% | $14.20 |
|
VNRX
VolitionRX Ltd.
|
$714.1K | -$0.04 | 272.5% | -33.67% | $2.20 |
|
VTAK
Catheter Precision, Inc.
|
$310K | -$0.20 | 118.75% | -11.57% | -- |
|
XTNT
Xtant Medical Holdings, Inc.
|
$30.8M | -- | -2.42% | -100% | $1.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
GCTK
GlucoTrack, Inc.
|
$3.90 | -- | $111.7M | -- | $0.00 | 0% | 6.72x |
|
CATX
Perspective Therapeutics, Inc.
|
$2.8100 | $12.3077 | $208.9M | -- | $0.00 | 0% | 190.53x |
|
INFU
InfuSystem Holdings, Inc.
|
$8.77 | $14.20 | $178.3M | 33.54x | $0.00 | 0% | 1.32x |
|
VNRX
VolitionRX Ltd.
|
$0.28 | $2.20 | $34M | -- | $0.00 | 0% | 18.97x |
|
VTAK
Catheter Precision, Inc.
|
$2.01 | -- | $2.5M | 0.40x | $0.00 | 0% | 9.45x |
|
XTNT
Xtant Medical Holdings, Inc.
|
$0.71 | $1.50 | $99.4M | 69.62x | $0.00 | 0% | 0.78x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
GCTK
GlucoTrack, Inc.
|
54.52% | 3.641 | 1.75% | 1.49x |
|
CATX
Perspective Therapeutics, Inc.
|
1.35% | 3.042 | 1.3% | 8.47x |
|
INFU
InfuSystem Holdings, Inc.
|
30.8% | 4.042 | 11.73% | 1.35x |
|
VNRX
VolitionRX Ltd.
|
-48.16% | 2.723 | 15.4% | 0.04x |
|
VTAK
Catheter Precision, Inc.
|
68.63% | 0.156 | 537.37% | 0.41x |
|
XTNT
Xtant Medical Holdings, Inc.
|
39.2% | 3.120 | 35.76% | 1.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
GCTK
GlucoTrack, Inc.
|
-$9K | -$4.3M | -2079.63% | -- | -- | -$4.7M |
|
CATX
Perspective Therapeutics, Inc.
|
-$566K | -$27.9M | -37.13% | -37.63% | -13330.62% | -$18.3M |
|
INFU
InfuSystem Holdings, Inc.
|
$20.3M | $3.8M | 6.43% | 9.93% | 10.45% | $8.4M |
|
VNRX
VolitionRX Ltd.
|
$318.2K | -$5.1M | -- | -- | -813.17% | -$3.5M |
|
VTAK
Catheter Precision, Inc.
|
-$320K | -$3M | -79.27% | -192.05% | -1336.73% | -$2.2M |
|
XTNT
Xtant Medical Holdings, Inc.
|
$22M | $2.5M | 2.15% | 3.78% | 7.64% | $4.2M |
GlucoTrack, Inc. vs. Competitors
-
Which has Higher Returns GCTK or CATX?
Perspective Therapeutics, Inc. has a net margin of -- compared to GlucoTrack, Inc.'s net margin of -12425.36%. GlucoTrack, Inc.'s return on equity of -- beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.
Company Gross Margin Earnings Per Share Invested Capital GCTKGlucoTrack, Inc.-- -$4.64 $6M CATXPerspective Therapeutics, Inc.-270.81% -$0.35 $245.5M -
What do Analysts Say About GCTK or CATX?
GlucoTrack, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 338%. Given that Perspective Therapeutics, Inc. has higher upside potential than GlucoTrack, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than GlucoTrack, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GCTKGlucoTrack, Inc.0 0 0 CATXPerspective Therapeutics, Inc.12 1 0 -
Is GCTK or CATX More Risky?
GlucoTrack, Inc. has a beta of 0.330, which suggesting that the stock is 66.993% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.151%.
-
Which is a Better Dividend Stock GCTK or CATX?
GlucoTrack, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GlucoTrack, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GCTK or CATX?
GlucoTrack, Inc. quarterly revenues are --, which are smaller than Perspective Therapeutics, Inc. quarterly revenues of $209K. GlucoTrack, Inc.'s net income of -$4.2M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, GlucoTrack, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GlucoTrack, Inc. is 6.72x versus 190.53x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GCTKGlucoTrack, Inc.6.72x -- -- -$4.2M CATXPerspective Therapeutics, Inc.190.53x -- $209K -$26M
-
Which has Higher Returns GCTK or INFU?
InfuSystem Holdings, Inc. has a net margin of -- compared to GlucoTrack, Inc.'s net margin of 6.19%. GlucoTrack, Inc.'s return on equity of -- beat InfuSystem Holdings, Inc.'s return on equity of 9.93%.
Company Gross Margin Earnings Per Share Invested Capital GCTKGlucoTrack, Inc.-- -$4.64 $6M INFUInfuSystem Holdings, Inc.55.65% $0.11 $80.2M -
What do Analysts Say About GCTK or INFU?
GlucoTrack, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand InfuSystem Holdings, Inc. has an analysts' consensus of $14.20 which suggests that it could grow by 61.92%. Given that InfuSystem Holdings, Inc. has higher upside potential than GlucoTrack, Inc., analysts believe InfuSystem Holdings, Inc. is more attractive than GlucoTrack, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GCTKGlucoTrack, Inc.0 0 0 INFUInfuSystem Holdings, Inc.5 0 0 -
Is GCTK or INFU More Risky?
GlucoTrack, Inc. has a beta of 0.330, which suggesting that the stock is 66.993% less volatile than S&P 500. In comparison InfuSystem Holdings, Inc. has a beta of 1.680, suggesting its more volatile than the S&P 500 by 68.01%.
-
Which is a Better Dividend Stock GCTK or INFU?
GlucoTrack, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystem Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GlucoTrack, Inc. pays -- of its earnings as a dividend. InfuSystem Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GCTK or INFU?
GlucoTrack, Inc. quarterly revenues are --, which are smaller than InfuSystem Holdings, Inc. quarterly revenues of $36.5M. GlucoTrack, Inc.'s net income of -$4.2M is lower than InfuSystem Holdings, Inc.'s net income of $2.3M. Notably, GlucoTrack, Inc.'s price-to-earnings ratio is -- while InfuSystem Holdings, Inc.'s PE ratio is 33.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GlucoTrack, Inc. is 6.72x versus 1.32x for InfuSystem Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GCTKGlucoTrack, Inc.6.72x -- -- -$4.2M INFUInfuSystem Holdings, Inc.1.32x 33.54x $36.5M $2.3M
-
Which has Higher Returns GCTK or VNRX?
VolitionRX Ltd. has a net margin of -- compared to GlucoTrack, Inc.'s net margin of -862.39%. GlucoTrack, Inc.'s return on equity of -- beat VolitionRX Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GCTKGlucoTrack, Inc.-- -$4.64 $6M VNRXVolitionRX Ltd.50.73% -$0.05 -$24.7M -
What do Analysts Say About GCTK or VNRX?
GlucoTrack, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 694.8%. Given that VolitionRX Ltd. has higher upside potential than GlucoTrack, Inc., analysts believe VolitionRX Ltd. is more attractive than GlucoTrack, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GCTKGlucoTrack, Inc.0 0 0 VNRXVolitionRX Ltd.4 2 0 -
Is GCTK or VNRX More Risky?
GlucoTrack, Inc. has a beta of 0.330, which suggesting that the stock is 66.993% less volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.234, suggesting its more volatile than the S&P 500 by 23.404%.
-
Which is a Better Dividend Stock GCTK or VNRX?
GlucoTrack, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GlucoTrack, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GCTK or VNRX?
GlucoTrack, Inc. quarterly revenues are --, which are smaller than VolitionRX Ltd. quarterly revenues of $627.3K. GlucoTrack, Inc.'s net income of -$4.2M is higher than VolitionRX Ltd.'s net income of -$5.4M. Notably, GlucoTrack, Inc.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GlucoTrack, Inc. is 6.72x versus 18.97x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GCTKGlucoTrack, Inc.6.72x -- -- -$4.2M VNRXVolitionRX Ltd.18.97x -- $627.3K -$5.4M
-
Which has Higher Returns GCTK or VTAK?
Catheter Precision, Inc. has a net margin of -- compared to GlucoTrack, Inc.'s net margin of -1037.17%. GlucoTrack, Inc.'s return on equity of -- beat Catheter Precision, Inc.'s return on equity of -192.05%.
Company Gross Margin Earnings Per Share Invested Capital GCTKGlucoTrack, Inc.-- -$4.64 $6M VTAKCatheter Precision, Inc.-141.59% -$1.70 $21.3M -
What do Analysts Say About GCTK or VTAK?
GlucoTrack, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Catheter Precision, Inc. has an analysts' consensus of -- which suggests that it could grow by 1790.6%. Given that Catheter Precision, Inc. has higher upside potential than GlucoTrack, Inc., analysts believe Catheter Precision, Inc. is more attractive than GlucoTrack, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GCTKGlucoTrack, Inc.0 0 0 VTAKCatheter Precision, Inc.0 0 0 -
Is GCTK or VTAK More Risky?
GlucoTrack, Inc. has a beta of 0.330, which suggesting that the stock is 66.993% less volatile than S&P 500. In comparison Catheter Precision, Inc. has a beta of -1.392, suggesting its less volatile than the S&P 500 by 239.195%.
-
Which is a Better Dividend Stock GCTK or VTAK?
GlucoTrack, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GlucoTrack, Inc. pays -- of its earnings as a dividend. Catheter Precision, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GCTK or VTAK?
GlucoTrack, Inc. quarterly revenues are --, which are smaller than Catheter Precision, Inc. quarterly revenues of $226K. GlucoTrack, Inc.'s net income of -$4.2M is lower than Catheter Precision, Inc.'s net income of -$2.3M. Notably, GlucoTrack, Inc.'s price-to-earnings ratio is -- while Catheter Precision, Inc.'s PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GlucoTrack, Inc. is 6.72x versus 9.45x for Catheter Precision, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GCTKGlucoTrack, Inc.6.72x -- -- -$4.2M VTAKCatheter Precision, Inc.9.45x 0.40x $226K -$2.3M
-
Which has Higher Returns GCTK or XTNT?
Xtant Medical Holdings, Inc. has a net margin of -- compared to GlucoTrack, Inc.'s net margin of 3.93%. GlucoTrack, Inc.'s return on equity of -- beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.
Company Gross Margin Earnings Per Share Invested Capital GCTKGlucoTrack, Inc.-- -$4.64 $6M XTNTXtant Medical Holdings, Inc.66.13% $0.01 $82.9M -
What do Analysts Say About GCTK or XTNT?
GlucoTrack, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 111.24%. Given that Xtant Medical Holdings, Inc. has higher upside potential than GlucoTrack, Inc., analysts believe Xtant Medical Holdings, Inc. is more attractive than GlucoTrack, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GCTKGlucoTrack, Inc.0 0 0 XTNTXtant Medical Holdings, Inc.2 0 0 -
Is GCTK or XTNT More Risky?
GlucoTrack, Inc. has a beta of 0.330, which suggesting that the stock is 66.993% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.077, suggesting its less volatile than the S&P 500 by 107.701%.
-
Which is a Better Dividend Stock GCTK or XTNT?
GlucoTrack, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GlucoTrack, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GCTK or XTNT?
GlucoTrack, Inc. quarterly revenues are --, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. GlucoTrack, Inc.'s net income of -$4.2M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, GlucoTrack, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 69.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GlucoTrack, Inc. is 6.72x versus 0.78x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GCTKGlucoTrack, Inc.6.72x -- -- -$4.2M XTNTXtant Medical Holdings, Inc.0.78x 69.62x $33.3M $1.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
69
RGC alert for Jan 7
Regencell Bioscience Holdings Ltd. [RGC] is up 58.95% over the past day.
Buy
69
WDC alert for Jan 7
Western Digital Corp. [WDC] is down 8.88% over the past day.
Buy
75
DRUG alert for Jan 7
Bright Minds Biosciences, Inc. [DRUG] is up 2.99% over the past day.
